MarketScreener Homepage > Equities > Nasdaq > Alnylam Pharmaceuticals, Inc. ALNY

Report

Delayed Nasdaq - 11/27 01:00:00 pm
129.86	USD		+3.52%

11/26

ALNYLAM PHARMACEUTICALS : to Webcast Presentation at 43rd Nasdaq Virtual Investor Conference

11/25

ALNYLAM PHARMACEUTICALS : Announces Innovative Value-Based Agreement Framework for OXLUMO to Accelerate Access for Patients with Primary Hyperoxaluria Type 1

11/25

ALNYLAM PHARMACEUTICALS : Announces U.S. Food and Drug Administration Approval of OXLUMO, the First and Only Treatment Approved for Primary Hyperoxaluria Type 1

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

11/20/2020	11/23/2020	11/24/2020	11/25/2020	11/27/2020	Date
124.7(c)	123.02(c)	125.66(c)	125.45(c)	129.86(c)	Last
425 632	493 691	872 439	512 765	265 015	Volume
+0.72%	-1.35%	+2.15%	-0.17%	+3.52%	Change

More quotes

Financials (USD)

Sales 2020	479 M - -
Net income 2020	-821 M - -
Net cash position 2020	1 206 M - -
P/E ratio 2020	-18,3x
Yield 2020	-

Sales 2021	804 M - -
Net income 2021	-680 M - -
Net cash position 2021	958 M - -
P/E ratio 2021	-22,9x
Yield 2021	-

Capitalization	15 087 M 15 087 M -
EV / Sales 2020	29,0x
EV / Sales 2021	17,6x
Nbr of Employees	1 323
Free-Float	99,2%

More Financials

Company

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic...

Sector

Biotechnology & Medical Research

Calendar

02/11

Earnings Release

More about the company

All news about ALNYLAM PHARMACEUTICALS, INC.

11/26	ALNYLAM PHARMACEUTICALS : to Webcast Presentation at 43rd Nasdaq Virtual Investo..	AQ
11/25	ALNYLAM PHARMACEUTICALS : Announces Innovative Value-Based Agreement Framework f..	AQ
11/25	ALNYLAM PHARMACEUTICALS : Announces U.S. Food and Drug Administration Approval o..	AQ
11/25	ALNYLAM PHARMACEUTICALS : to Webcast Presentation at 43rd Nasdaq Virtual Investo..	BU
11/24	ALNYLAM PHARMACEUTICALS : Conference Call to Discuss FDA Approval of OXLUMO&trad..	PU
11/24	ALNYLAM PHARMACEUTICALS : Announces Innovative Value-Based Agreement Framework f..	BU
11/24	ALNYLAM PHARMACEUTICALS : Announces U.S. Food and Drug Administration (FDA) Appr..	BU
11/20	ALNYLAM PHARMACEUTICALS : Receives Approval for OXLUMO in the European Union for..	AQ
11/19	ALNYLAM PHARMACEUTICALS : Receives Approval for OXLUMO™ (lumasiran) in the..	BU
11/13	ALNYLAM PHARMACEUTICALS : Reports Positive Interim Results from Ongoing Phase 1 ..	BU
11/06	ALNYLAM PHARMACEUTICALS : Reports Third Quarter 2020 Financial Results and Highl..	AQ
11/05	ALNYLAM : 3Q Earnings Snapshot	AQ
11/05	ALNYLAM PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..	AQ
11/05	ALNYLAM PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, F..	AQ
11/05	ALNYLAM PHARMACEUTICALS : Reports Third Quarter 2020 Financial Results and Highl..	BU

More news

News in other languages on ALNYLAM PHARMACEUTICALS, INC.

11/20	ALNYLAM PHARMACEUTICALS : erhält EU-Zulassung für OXLUMO™ (Lumasiran) zur ..
11/20	ALNYLAM PHARMACEUTICALS : reçoit l'approbation de l'Union européenne pour OXLUMO..
10/18	ALNYLAM PHARMACEUTICALS : reçoit un avis positif du CHMP pour OXLUMO™ (lum..
10/17	ALNYLAM PHARMACEUTICALS : erhält positive CHMP-Stellungnahme für OXLUMO™ (..
10/16	NOVARTIS : le CHMP recommande un nouvel anticholestérol

More news

Analyst Recommendations on ALNYLAM PHARMACEUTICALS, INC.

2018	Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom	RE
2016	ALNYLAM PHARMACEUTICALS : Ionis shares plummet as GSK scraps heart drug trial pl..	RE
2014	Sanofi use of cash scrutinised as L'Oreal stake buyback fades	RE

More recommendations

Provided by Scoopnest.com

Chart ALNYLAM PHARMACEUTICALS, INC.

Duration : Period :

Alnylam Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends ALNYLAM PHARMACEUTICALS, INC.

	Short Term	Mid-Term	Long Term
Trends	Neutral	Neutral	Neutral

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	OUTPERFORM
Number of Analysts	24
Average target price	163,04 $
Last Close Price	129,86 $
Spread / Highest target	73,3%
Spread / Average Target	25,6%
Spread / Lowest Target	-28,4%

Consensus

EPS Revisions

More Estimates Revisions

Managers

Name	Title
John M. Maraganore	Chief Executive Officer & Director
Yvonne L. Greenstreet	President & Chief Operating Officer
Michael W. Bonney	Chairman
Jeffrey Poulton	Chief Financial & Accounting Officer
Akshay K. Vaishnaw	President-Research & Development

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

ALNYLAM PHARMACEUTICALS, INC.	12.76%	15 087



IQVIA HOLDINGS INC.	9.26%	32 365
HANGZHOU TIGERMED CONSULTING CO.,LTD	79.46%	15 070
PRA HEALTH SCIENCES, INC.	-0.14%	7 120
SYNEOS HEALTH, INC.	12.08%	6 932
NOVAVAX, INC.	2,477.89%	6 427

More Results